Sarepta Therapeutics Inc
Sarepta Therapeutics Inc (SRPT) Straddle
SRPT straddle scan found 159 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 59.9%.
Read more
Trading a SRPT straddle lets you take a pure volatility position on Sarepta Therapeutics Inc without committing to a direction. Sarepta Therapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate SRPT straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on SRPT profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Sarepta Therapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the SRPT straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.
It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the SRPT straddle is the cleanest expression of that view. Our scanner prices every SRPT straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a SRPT straddle into a catalyst or short a SRPT straddle to harvest decay, the options straddle setups that matter are all in one place.
| Jan 19, 2029 | 32.50 | $21.75 | 855 | 45% | 59.9% | $54.25 | $10.75 | 0 |
| Jan 21, 2028 | 40.00 | $24.48 | 491 | 45% | 59.5% | $64.48 | $15.53 | 10 |
| Jan 21, 2028 | 37.50 | $22.60 | 491 | 45% | 58.6% | $60.10 | $14.90 | 4 |
| Dec 17, 2027 | 40.00 | $24.50 | 456 | 45% | 58.0% | $64.50 | $15.50 | 1 |
| Jan 19, 2029 | 30.00 | $20.25 | 855 | 45% | 57.9% | $50.25 | $9.75 | 0 |
| Jan 15, 2027 | 45.00 | $24.63 | 120 | 45% | 57.1% | $69.63 | $20.38 | 0 |
| Dec 17, 2027 | 37.50 | $22.63 | 456 | 45% | 57.1% | $60.13 | $14.88 | 0 |
| Jan 21, 2028 | 35.00 | $21.00 | 491 | 45% | 56.9% | $56.00 | $14.00 | 1 |
| Jan 15, 2027 | 50.00 | $29.65 | 120 | 45% | 56.8% | $79.65 | $20.35 | 0 |
| Oct 9, 2026 | 22.00 | $2.65 | 22 | 45% | 56.8% | $24.65 | $19.35 | 3 |
As of September 17, 2026
Find the right straddle before volatility moves
Track SRPT straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→